Relative Risk of Cardiovascular Mortality in Breast Cancer Patients: A Population-Based Study

Abstract

Aims:To investigate the risk of cardiovascular disease (CVD) mortality in breast cancer patients compared with the general female population. Methods: Data was retrieved from the Surveillance, Epidemiology, and End Results database. 924,439 female breast cancer patients who were at the age of follow-up ≥30 years and diagnosed during 1990-2016 as well as the aggregated general female population in the US were included. Using multivariable Poisson regression, we calculated incidence rate ratios (IRRs) of CVD mortality among female breast cancer patients compared with the female population. Results: The risk of CVD mortality was mildly increased among breast cancer patients at the age of follow-up 30-64 years (IRR 1.06, 95% confidence interval [CI] 1.03-1.10) compared with the general population. This growth of risk reached its peak within the first month after diagnosis (IRR 3.33, 95% CI 2.84-3.91) and was mainly activated by diseases of the heart (IRR 1.11, 95% CI 1.07-1.15). The elevation was greatest in survivors at the age of follow up 30-34 years (IRR 3.50, 95% CI 1.75-7.01). Conclusions: Clinicians should provide risk mitigation strategies with early monitoring of CVD mortality for breast cancer survivors, especially those who were young or with aggressive tumor stage.

Role of Clinical Risk Factors and B-Type Natriuretic Peptide in Assessing the Risk of Asymptomatic Cardiotoxicity in Breast Cancer Patients in Kazakhstan

“…We suppose this is related to the following circumstances: the model was primarily designed for those who received anthracycline therapy, and younger age at diagnosis is a significant risk factor, at least for pediatric patients on anthracycline therapy [63]. Chinese researchers showed that the risk of CVD mortality was increased among breast cancer patients at the age of follow-up 30-64 years and was mainly activated by heart diseases [7]. In addition, predictors are unequal by weight and significance within the hierarchy.…”

“…It has been established that BC survivors are three times more likely to develop heart failure (HF) within five years of cancer diagnosis than the general population [6]. According to Chinese researchers, the most vulnerable period is 30-64 years, and the risk peaks within the first months after diagnosis [7]. This worrisome trend is mainly explained by the cardiotoxic effects of chemo-and radiotherapy.…”

Cardiotoxicity of Anthracycline-based Chemotherapy in Breast Cancer Patients: A Case Series

“…It has been established that BC survivors are three times more likely to develop heart failure (HF) within 5 years of cancer diagnosis than the general population [6]. According to Chinese researchers, the most vulnerable period for cardiovascular events development in BC patients, including death, is 30-64 years, it has been observed that the risk peaks usually within the first few months after diagnosis [7]. Сardiovascular complications in cancer patients include coronary artery disease, hypertension, QT prolongation, arrhythmias, stroke, peripheral arterial disease, valvular heart disease, pericardial disease, and venous thromboembolism.…”